Novartis Glivec Make It Through NICE For GISTs With Expanded Label
This article was originally published in The Pink Sheet Daily
Executive Summary
After a prior rejection, Britain’s NICE has backed Novartis’ Glivec for KIT (CD117)-positive GISTS, even accepting an expanded-treatment duration of three years compared to the original single year.
You may also be interested in...
Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.